Silexion Therapeutics Requests Hearing on Nasdaq Delisting

Silexion Therapeutics ( (SLXN) ) has shared an update.

On May 28, 2025, Silexion Therapeutics Corp requested a hearing regarding a delisting notice from Nasdaq due to non-compliance with specific listing rules. The company plans to transfer its securities to the Nasdaq Capital Market, subject to meeting the required equity standards, but there is no guarantee of success.

The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.

Spark’s Take on SLXN Stock

According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.

Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.

To see Spark’s full report on SLXN stock, click here.

More about Silexion Therapeutics

Silexion Therapeutics Corp is a company based in the Cayman Islands, operating in the biotechnology industry. The company is primarily focused on developing therapeutic solutions and is listed on the Nasdaq Global Market.

Average Trading Volume: 3,214,513

Technical Sentiment Signal: Sell

Current Market Cap: $8.34M

See more insights into SLXN stock on TipRanks’ Stock Analysis page.